Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Second primary cancers in long-term survivors of glioblastoma.

Kim JY, Jackman JG, Woodring S, McSherry F, Herndon JE, Desjardins A, Friedman HS, Peters KB.

Neurooncol Pract. 2019 Sep;6(5):386-391. doi: 10.1093/nop/npz001. Epub 2019 Feb 4.

PMID:
31555453
2.

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Patel MP, Woodring S, Randazzo DM, Friedman HS, Desjardins A, Healy P, Herndon JE 2nd, McSherry F, Lipp ES, Miller E, Peters KB, Affronti ML.

Support Care Cancer. 2019 Aug 22. doi: 10.1007/s00520-019-05039-x. [Epub ahead of print]

PMID:
31440823
3.

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

Randazzo DM, McSherry F, Herndon JE, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Boulton S, Desjardins A, Ashley DM, Friedman HS, Peters KB.

Complement Ther Clin Pract. 2019 Aug;36:43-48. doi: 10.1016/j.ctcp.2019.05.002. Epub 2019 May 18.

PMID:
31383442
4.

ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.

Tsvankin V, Hashizume R, Katagi H, Herndon JE, Lascola C, Venkatraman TN, Picard D, Burrus B, Becher OJ, Thompson EM.

Neurosurgery. 2019 Jun 21. pii: nyz212. doi: 10.1093/neuros/nyz212. [Epub ahead of print]

PMID:
31225627
5.

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

Desjardins A, Herndon JE 2nd, McSherry F, Ravelo A, Lipp ES, Healy P, Peters KB, Sampson JH, Randazzo D, Sommer N, Friedman AH, Friedman HS.

Health Sci Rep. 2019 Feb 13;2(4):e114. doi: 10.1002/hsr2.114. eCollection 2019 Apr.

6.

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, Grenier C, Huang Z, Murphy SK, McLendon RE, Friedman HS, Friedman AH, Herndon JE 2nd, Sampson JH, Keir ST, Bigner DD, Yan H, He Y.

Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.

PMID:
31040154
7.

Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE.

Nat Med. 2019 Mar;25(3):529. doi: 10.1038/s41591-019-0355-0.

PMID:
30670876
8.

MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.

Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE.

J Neuropathol Exp Neurol. 2019 Jan 1;78(1):57-64. doi: 10.1093/jnen/nly110.

PMID:
30500933
9.

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.

Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE 2nd, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L.

Clin Cancer Res. 2019 Jan 1;25(1):358-368. doi: 10.1158/1078-0432.CCR-18-1211. Epub 2018 Nov 13.

PMID:
30425092
10.

Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.

Affronti ML, Randazzo D, Lipp ES, Peters KB, Herndon SC, Woodring S, Healy P, Cone CK, Herndon JE 2nd, Schneider SM.

Semin Oncol Nurs. 2018 Dec;34(5):472-485. doi: 10.1016/j.soncn.2018.10.006. Epub 2018 Nov 6. Review.

PMID:
30409554
11.

Adjunctive perampanel for glioma-associated epilepsy.

Dunn-Pirio AM, Woodring S, Lipp E, Herndon JE 2nd, Healy P, Weant M, Randazzo D, Desjardins A, Friedman HS, Peters KB.

Epilepsy Behav Case Rep. 2018 Oct 9;10:114-117. doi: 10.1016/j.ebcr.2018.09.003. eCollection 2018.

12.

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE.

Nat Med. 2018 Sep;24(9):1459-1468. doi: 10.1038/s41591-018-0135-2. Epub 2018 Aug 13. Erratum in: Nat Med. 2019 Mar;25(3):529.

13.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

14.

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE 2nd, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L.

Oncoimmunology. 2018 Feb 21;7(6):e1434464. doi: 10.1080/2162402X.2018.1434464. eCollection 2018.

15.

The clinical importance of medulloblastoma extent of resection: a systematic review.

Thompson EM, Bramall A, Herndon JE 2nd, Taylor MD, Ramaswamy V.

J Neurooncol. 2018 Sep;139(3):523-539. doi: 10.1007/s11060-018-2906-5. Epub 2018 May 23. Review.

PMID:
29796724
16.

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy PN, Herndon JE 2nd, McLendon RE, Keir ST, Archer GE, Reap EA, Sanchez-Perez L, Bigner DD, Sampson JH.

Clin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.

17.

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Affronti ML, Jackman JG, McSherry F, Herndon JE 2nd, Massey EC Jr, Lipp E, Desjardins A, Friedman HS, Vlahovic G, Vredenburgh J, Peters KB.

Oncologist. 2018 Aug;23(8):889-e98. doi: 10.1634/theoncologist.2018-0149. Epub 2018 Apr 17.

18.

Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.

Nilsen TS, Scott JM, Michalski M, Capaci C, Thomas S, Herndon JE 2nd, Sasso J, Eves ND, Jones LW.

Med Sci Sports Exerc. 2018 Jun;50(6):1134-1141. doi: 10.1249/MSS.0000000000001545.

19.

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Peters KB, Lipp ES, Miller E, Herndon JE 2nd, McSherry F, Desjardins A, Reardon DA, Friedman HS.

J Neurooncol. 2018 Apr;137(2):349-356. doi: 10.1007/s11060-017-2724-1. Epub 2017 Dec 21.

PMID:
29264836
20.

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.

Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp ES, Herndon JE 2nd, McSherry F, Desjardins A, Randazzo D, Friedman HS, Peters KB.

Oncologist. 2018 Feb;23(2):157-e21. doi: 10.1634/theoncologist.2017-0501. Epub 2017 Nov 13.

21.

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE 2nd, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH.

Cancer Res. 2018 Jan 1;78(1):256-264. doi: 10.1158/0008-5472.CAN-17-0469. Epub 2017 Nov 1.

22.

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Randazzo DM, McSherry F, Herndon JE 2nd, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman HS, Keir S, Peters KB.

J Neurooncol. 2017 Sep;134(2):363-369. doi: 10.1007/s11060-017-2535-4. Epub 2017 Jul 1.

PMID:
28669010
23.

Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE, Hoang JK, Yin FF, Sampson JH, Fecci PE, Blackwell KL, Kirkpatrick JP, Kim GJ.

Neuro Oncol. 2017 Oct 1;19(10):1391-1397. doi: 10.1093/neuonc/nox090.

24.

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH.

Clin Cancer Res. 2017 Apr 15;23(8):1898-1909. doi: 10.1158/1078-0432.CCR-16-2057.

25.

Rethinking Autoantibody Signature Panels for Cancer Diagnosis.

Campa MJ, Gottlin EB, Herndon JE 2nd, Patz EF Jr.

J Thorac Oncol. 2017 Jun;12(6):1011-1014. doi: 10.1016/j.jtho.2017.01.017. Epub 2017 Jan 23.

26.

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Affronti ML, Woodring S, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS.

Ther Clin Risk Manag. 2016 Dec 23;13:33-40. doi: 10.2147/TCRM.S122480. eCollection 2017.

27.

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Kelley MJ, Jha G, Shoemaker D, Herndon JE 2nd, Gu L, Barry WT, Crawford J, Ready N.

Cancer Invest. 2017 Jan 2;35(1):32-35. doi: 10.1080/07357907.2016.1253710. Epub 2016 Dec 2.

PMID:
27911119
28.

X-Ray Psoralen Activated Cancer Therapy (X-PACT).

Oldham M, Yoon P, Fathi Z, Beyer WF, Adamson J, Liu L, Alcorta D, Xia W, Osada T, Liu C, Yang XY, Dodd RD, Herndon JE 2nd, Meng B, Kirsch DG, Lyerly HK, Dewhirst MW, Fecci P, Walder H, Spector NL.

PLoS One. 2016 Sep 1;11(9):e0162078. doi: 10.1371/journal.pone.0162078. eCollection 2016.

29.

Insomnia and its associations in patients with recurrent glial neoplasms.

Robertson ME, McSherry F, Herndon JE, Peters KB.

Springerplus. 2016 Jun 21;5(1):823. doi: 10.1186/s40064-016-2578-6. eCollection 2016.

30.

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Affronti ML, Woodring S, Allen K, Kirkpatrick J, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS.

Support Care Cancer. 2016 Oct;24(10):4365-75. doi: 10.1007/s00520-016-3276-1. Epub 2016 Jun 6.

PMID:
27271867
31.

Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.

Saraswathula A, Reap EA, Choi BD, Schmittling RJ, Norberg PK, Sayour EJ, Herndon JE 2nd, Healy P, Congdon KL, Archer GE, Sanchez-Perez L, Sampson JH.

Cancer Immunol Immunother. 2016 Feb;65(2):205-11. doi: 10.1007/s00262-015-1784-3. Epub 2016 Jan 12.

32.

Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography".

Kwon W, Howard BA, Herndon JE, Patz EF Jr.

J Thorac Oncol. 2015 Oct;10(10):e102. doi: 10.1097/JTO.0000000000000637. No abstract available.

33.

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

Peters KB, Lou E, Desjardins A, Reardon DA, Lipp ES, Miller E, Herndon JE 2nd, McSherry F, Friedman HS, Vredenburgh JJ.

Oncologist. 2015 Jul;20(7):727-8. doi: 10.1634/theoncologist.2015-0135. Epub 2015 May 29.

34.

Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity.

Wysham NG, Miriovsky BJ, Currow DC, Herndon JE 2nd, Samsa GP, Wilcock A, Abernethy AP.

J Pain Symptom Manage. 2015 Oct;50(4):480-7. doi: 10.1016/j.jpainsymman.2015.04.015. Epub 2015 May 22.

35.

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.

Kwon W, Howard BA, Herndon JE, Patz EF Jr.

J Thorac Oncol. 2015 Jun;10(6):897-902. doi: 10.1097/JTO.0000000000000534.

36.

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH.

Nature. 2015 Mar 19;519(7543):366-9. doi: 10.1038/nature14320. Epub 2015 Mar 11.

37.

Prognostic marker analysis in pediatric intracranial ependymomas.

McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, Perkinson K, Lefaivre M, Zagzag D, Wiener B, Gururangan S, Fuchs H, Friedman HS, Herndon JE 2nd, Healy P.

J Neurooncol. 2015 Apr;122(2):255-61. doi: 10.1007/s11060-014-1711-z. Epub 2015 Jan 7.

PMID:
25563815
38.

Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study.

Tuchman SA, Lane A, Hornsby WE, Bishop C, Thomas S, Herndon JE 2nd, Long G, Gasparetto C, Jones LW.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):103-9. doi: 10.1016/j.clml.2014.09.002. Epub 2014 Sep 28.

PMID:
25445473
39.

Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.

Kirkpatrick JP, Wang Z, Sampson JH, McSherry F, Herndon JE 2nd, Allen KJ, Duffy E, Hoang JK, Chang Z, Yoo DS, Kelsey CR, Yin FF.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):100-8. doi: 10.1016/j.ijrobp.2014.09.004. Epub 2014 Oct 21.

PMID:
25442342
40.

Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.

Weitzel DH, Tovmasyan A, Ashcraft KA, Rajic Z, Weitner T, Liu C, Li W, Buckley AF, Prasad MR, Young KH, Rodriguiz RM, Wetsel WC, Peters KB, Spasojevic I, Herndon JE 2nd, Batinic-Haberle I, Dewhirst MW.

Mol Cancer Ther. 2015 Jan;14(1):70-9. doi: 10.1158/1535-7163.MCT-14-0343. Epub 2014 Oct 15.

41.

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.

Peters KB, West MJ, Hornsby WE, Waner E, Coan AD, McSherry F, Herndon JE 2nd, Friedman HS, Desjardins A, Jones LW.

J Neurooncol. 2014 Dec;120(3):499-506. doi: 10.1007/s11060-014-1574-3. Epub 2014 Aug 13.

42.

Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.

Kelsey CR, Scott JM, Lane A, Schwitzer E, West MJ, Thomas S, Herndon JE 2nd, Michalski MG, Horwitz ME, Hennig T, Jones LW.

Bone Marrow Transplant. 2014 Oct;49(10):1330-6. doi: 10.1038/bmt.2014.159. Epub 2014 Jul 28.

43.

Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients.

Kenjale AA, Hornsby WE, Crowgey T, Thomas S, Herndon JE 2nd, Khouri MG, Lane AR, Bishop CE, Eves ND, Peppercorn J, Douglas PS, Jones LW.

Oncologist. 2014 Sep;19(9):999-1005. doi: 10.1634/theoncologist.2014-0078. Epub 2014 Jul 24.

44.

A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.

Kanaly CW, Mehta AI, Ding D, Hoang JK, Kranz PG, Herndon JE 2nd, Coan A, Crocker I, Waller AF, Friedman AH, Reardon DA, Sampson JH.

J Neurosurg. 2014 Sep;121(3):536-42. doi: 10.3171/2014.4.JNS121952. Epub 2014 Jul 18.

45.

Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.

Crowgey T, Peters KB, Hornsby WE, Lane A, McSherry F, Herndon JE 2nd, West MJ, Williams CL, Jones LW.

Appl Physiol Nutr Metab. 2014 Jun;39(6):724-9. doi: 10.1139/apnm-2013-0380. Epub 2013 Dec 3.

46.

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE 2nd, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH.

PLoS One. 2014 Apr 10;9(4):e94281. doi: 10.1371/journal.pone.0094281. eCollection 2014.

47.

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD.

Oncotarget. 2014 Mar 30;5(6):1515-25.

48.

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Choi BD, Gedeon PC, Herndon JE 2nd, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH.

Cancer Immunol Res. 2013 Sep;1(3):163. doi: 10.1158/2326-6066.CIR-13-0049.

49.

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.

Affronti ML, Schneider SM, Herndon JE 2nd, Schlundt S, Friedman HS.

Support Care Cancer. 2014 Jul;22(7):1897-905. doi: 10.1007/s00520-014-2136-0. Epub 2014 Feb 26.

50.

Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.

Khouri MG, Hornsby WE, Risum N, Velazquez EJ, Thomas S, Lane A, Scott JM, Koelwyn GJ, Herndon JE, Mackey JR, Douglas PS, Jones LW.

Breast Cancer Res Treat. 2014 Feb;143(3):531-9. doi: 10.1007/s10549-013-2818-1. Epub 2014 Jan 4.

Supplemental Content

Loading ...
Support Center